


Claims:

1. A compound having the general structure:



10 wherein R₁, R₇ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R₃ is hydroxy or -OCONH₂; and


R₄ is hydroxy or carbonyl.

15 2. The compound of claim 1 wherein R₁ is H or halo; and

R₇ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy.

20 3. The compound of claim 2 wherein R₄, R₇ and R₈ are H; and
R₁ is H or F.

4. A compound having the general structure:



25 wherein R₁, R₇ and R₈ are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂, with the proviso that at least one of R₁, R₇ and R₈ is other than H.


30 5. The compound of claim 4 wherein R₇ and R₈ are H;
R₁ is F; and

Paul A
25

A1
cont

R₃ is hydroxy or -OCONH₂.

6. A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound selected from the group consisting of




wherein R₁, R₇, R₈ and R₉ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R₃ is hydroxy or -OCONH₂; and

R₄ is hydroxy or carbonyl, with the proviso that when R₉ is H, R₇ and R₈ are not both H.

7. The method of claim 6 wherein said compound has the general structure





wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and


R_3 is hydroxy or $-OCONH_2$.

8. The method of claim 7 wherein R_1 is H; and
 R_3 is $-OCONH_2$.

9. A method for treating a patient suffering from tissue damage resulting from localized hypoxic conditions, said method comprising the step of administering a composition comprising a compound selected from the group consisting of



and




wherein R_1 , R_7 , R_8 and R_9 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R_3 is hydroxy or $-OCONH_2$; and

25 R_4 is hydroxy or carbonyl, with the proviso that when R_9 is H, R_7 and R_8 are not both H..

10. The method of claim 9 wherein said compound has the general structure



wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.


15 11. The method of claim 10 wherein R_1 is H; and
 R_3 is $-OCONH_2$.

12. The method of claim 9 wherein the localized hypoxic condition is caused by cerebral ischemia.


20 13. The method of claim 9 wherein the localized hypoxic condition is caused by myocardial ischemia.

25 14. A pharmaceutical composition comprising a compound selected from the group consisting of

add
A2



10



wherein R₁, R₇, R₈ and R₉ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

15 R₃ is hydroxy or -OCONH₂; and


R₄ is hydroxy or carbonyl, with the proviso that when R₉ is H, R₇ and R₈ are not both H; and

a pharmaceutically acceptable carrier.,

20

15. The composition of claim 14 wherein said compound has the general structure

25



30

wherein R_1 is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCONH_2$.

5

16. The composition of claim 15 wherein R_1 is selected from the group consisting of halo, haloalkyl and hydroxy.

10

17. The composition of claim 15 wherein R_1 is H; and
 R_3 is $-OCONH_2$.

TOP SECRET//
REF ID: A65650